1 / 40

Assessing Response in Malignant Lymphoma

Assessing Response in Malignant Lymphoma. Lieselot Brepoels Sigrid Stroobants UZ Gasthuisberg, Leuven, Belgium. Introduction. Wide range of pathobiologically distinct diseases (REAL/WHO classification) 1. Hodgkin’s disease/lymphoma 2. Non-Hodgkin’s lymphoma Difficulties: Multiple sites

faraji
Télécharger la présentation

Assessing Response in Malignant Lymphoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Assessing Response in Malignant Lymphoma Lieselot Brepoels Sigrid Stroobants UZ Gasthuisberg, Leuven, Belgium

  2. Introduction • Wide range of pathobiologically distinct diseases (REAL/WHO classification) • 1. Hodgkin’s disease/lymphoma • 2. Non-Hodgkin’s lymphoma • Difficulties: • Multiple sites • Different entities have different FDG avidity, different clinical behaviour, different treatment modalities • Working diagnosis • -“Aggressive” subtypes • - “Indolent” subtypes

  3. Classification of lymphoma (WHO-classification) T-Cell and Natural Killer Cell Neoplasms I. Precursor T cell neoplasm: a. Precursor T-lymphoblastic lymphoma/leukemia b. Blastic NK lymphoma II. Mature (peripheral) T cell and NK-cell neoplasms a. T cell prolymphocytic leukemia b. T-cell granular lymphocytic leukemia c. Aggressive NK Cell leukemia d. Adult T cell lymphoma/leukemia (HTLV1+) e. Extranodal NK/T-cell lymphoma, nasal type f. Enteropathy-type T-cell lymphoma g. Hepatosplenic gamma-delta T-cell lymphoma h. Subcutaneous panniculitis-like T-cell lymphoma i. Mycosis fungoides/Sézary's syndrome j. Primary Cutaneous Anaplastic large cell lymphoma T/null cell k. Peripheral T cell lymphoma, unspecified l. Angioimmunoblastic T cell lymphoma m.Primary Systemic Anaplastic large cell lymphoma, T/null cell T-cell proliferation of uncertain malignant potential Lymphomatoid papulosis Lymphomas by Location Central Nervous System (CNS) Lymphoma Lymphoma of Bone Eyelid Lymphoma (new) Digestive Tract Lymphoma Ocular (Eye) Lymphoma (new) Hodgkin's Lymphoma (Hodgkin's Disease) (B Cell Origin) a. Nodular lymphocyte predominance Hodgkin's lymphoma b. Classical Hodgkin's lymphoma Nodular sclerosis Hodgkin's lymphoma Lymphocyte-rich classical Hodgkin's lymphoma Mixed cellularity Hodgkin's lymphoma Lymphocyte depletion Hodgkin's lymphoma B-Cell Neoplasms I. Precursor B-cell neoplasm: a. Precursor B-lymphoblastic leukemia/lymphoma II. Mature (peripheral) B-cell neoplasms a. B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma b. B-cell prolymphocytic leukemia c. Lymphoplasmacytic lymphoma d. Splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) e. Nodal marginal zone lymphoma (+/- monocytoid B-cells) f. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type g. Hairy cell leuekmia h. Plasma cell myeloma/plasmacytoma i. Follicular lymphoma, follicle center j. Mantle cell lymphoma k. Diffuse large cell B-cell lymphoma Mediastinal large B-cell lymphoma Intravascular large B-cell lymphoma Primary effusion lymphoma l. Burkitt's lymphoma/Burkitt's cell leukemia B-cell proliferations of uncertain malignant potential Lymphomatoid granulomatosis Post-transplant lymphoproliferative disorder Childhood lymphoma lymphoblastic lymphoma (30%) Burkitt's lymphoma (40%) Anaplastic Large Cell Lymphoma (10%) large B-cell lymphoma (20%) • Working diagnosis (NHL) • “Aggressive” subtypes: fast progression, potentially curable • “Indolent” subtypes: slow progression, considered incurable

  4. 511 KeV 511 KeV 18F + 180o - Positron emission tomography > 60 min 45 min start scan from pelvis upto head Injection FDG fasting No glucose containing infuses

  5. Metabolic imaging:FDG tumor model Tumor cell Normal cell Glucose 6-phosphatase Glucose 6-phosphatase FDG FDG-6-P FDG-6-P Glycolytic pathway Glycolytic pathway Hexokinase Hexokinase G6P G6P Glucose 6-phosphatase Glucose 6-phosphatase D-glucose (inflammatory cells) standardized uptake value (SUV)= FDG-uptake/g in a lesion Injected dose/weight

  6. Indication for FDG-PET in Lymphoma • Staging and restaging after treatment • Revised reponse criteria IWC+PET • PET as a prognostic markerearly during treatment

  7. Need for an accurate and sensitive tool to detect residual disease End-of-treatment PET in Lymphoma • Residual masses at the end of therapy are frequent (70% HD, 50% NHL) but only a minority of pts relapse (<20% HD, 25% NHL) • late toxic effects of treatment are increasingly recognized • Patients in apparent complete remission also relapse • Early treatment of residual disease may improve survival

  8. PET for evaluation of residual disease in Hodgkin’s Lymphoma

  9. End-of-treatment PET in NHL Systematic review Zijlstra et al, Haematologica 2006 NHL sub-analysis, n=201

  10. New Revised Response Criteria in Lymphoma International Harmonisation Working Group Juweid et al, JCO February 2007 Bruce Cheson et al., JCO February 2007 • Aim = Revision of the 1999 guidelines (CT-based) for response assessment and outcome measurements 1. Standardization of PET-response 2. Update of CT-based guidelines 3. Combination of PET and CT-results

  11. PET in Lymphoma standardization and interpretation Juweid et al, JCO February 2007 • Image acquisition for PET and PET/CT • Image interpretation • PET+ = uptake > local background and incompatible with normal anatomy/physiology Exception: • residualmass > 2 cm, uptake ≤ mediastinal BG = PET negative • additional guidelines • Liver and Spleen • Diffuse uptake in spleen is positive if > liver uptake • Focal lesions > 1.5 cm must appear photopenic to be PET negative • Bone marrow • Focal higher than BG (no BMB+ necessary to confirm involvement)

  12. residual mass > 2 cm • uptake ≤ mediastinal BG • = PET negative Positivity on PET? • residual mass < 2 cm • uptake > local BG • = PET positive

  13. Assessment of splenic involvement D C A B Increased FDG-uptake in the spleen in 4 patients with Hodgkin’s Lymphoma (HL). While patient A is a classical example of diffusely increased FDG-uptake in an enlarged spleen, patient B presented with a normal sized spleen with only slightly increased FDG-uptake compared to liver uptake. Both patients had diffuse splenic involvement by HL. Focal lesions in the spleen were seen in patient C, which were caused by lymphoma involvement. Although patient D was initially thought to have residual disease in the spleen based on a heterogenous uptake, microscopic examination showed only arguments for extramedullary hematopoiesis.

  14. CRu if > 75% reduction in SPD IWC Cheson et al. JCO 1999 Combination of PET and CTIWC+PET criteria Cheson et al, JCO February 2007 CR regardless of response on CT - PR if > 50% reduction in SPD SD if < 50% reduction in SPD PD or Relapse if new lesion or > 50% increase of a known lesion PET + CT Only adviced for end-of-treatment evaluation in routinely FDG-avid and potentially curable lymphoma !

  15. Patiënt 1 CRu (SPD – 84%) Patiënt 2 PR (SPD – 55%)

  16. IWC+PET in Hodgkin’s Lymphoma Brepoels, Stroobants et al. 2007 Data Spaepen, Br J Haematol. 2001 Updated and IWC + PET response in 56 pts with Hodgkin’s lymphoma PET at the end of first line R/ (after additional radiotherapy)

  17. IWC+PET in Aggressive NHL IWC IWC+PET CR CR SD CRu PR PR PD PD SD Brepoels, Stroobants et al., 2007 Data Spaepen, JCO 2000 PET after first line R/ Updated and IWC + PET response in 55 pts with routinely FDG-avid and potentially curable (aggressive) NHL

  18. No additional value of IWC+PET in Indolent NHL ? Brepoels, Stroobants et al., 2007 Data Spaepen, JCO 2000 PET after first line R/ Updated and IWC + PET response in 14 pts with not-routinely FDG-avid and incurable NHL(8 FL, 4 MCL, 2 MZL)

  19. 13 FDG uptake and grading Schöder et al. JCO 2005 Aggressive N=63 DLBCL 55 FL gr III 7 PTCL 1 Indolent N=28 FL gr I 11 FL gr II 4 MZL 4 small cell 8

  20. FDG uptake and grading Schöder et al. JCO 2005 • MCL: • Tendency to relapse • PET presentation as indolent • agressive disease course

  21. Staging of Mantle cell lymphoma MCL-BV (median SUV 16.88) versus common MCL (median 6.79) (p=0.00006).

  22. Response criteria in MCL? CT-based criteria (IHP) CR: disappearance of all detectable disease PR: decrease > 50% SPD SD: decrease < 50% SPD PD: new lesion or >50% SPD PET-based criteria (EORTC) CMR: PET negative PMR: SUV decrease > 25% SMD: SUV decrease < 25% PMD: SUV increase >25% or new lesion IWC+PET criteria CR: everything if PET negative PR/SD/PD idem as CT-based criteria if PET is positive

  23. Additional value of IWC+PET in MCL ? Different response categories have different prognosis No prognostic difference between responders Non-responders are the same as with CT alone

  24. Additional value of IWC+PET in MCL ?

  25. Revised Response Criteria in Lymphoma • Use of IWC+PET criteria • essential at the end of treatment in routinely FDG-avid and potentially curable lymphoma (DLBCL and HD) • Limitations • Only recommended for end-of-treatment evaluation • value has to be established in the other histological subtypes, no encouraging results in Mantle cell lymphoma • Only assessment of negative or positive on PET, no quantitative evaluation of response !

  26. PET as a prognostic marker early during therapy • A substantial number of patients are not cured with standard chemotherapy early change of therapy might improve outcome • Late treatment related morbidity and mortality especially after combination chemoradiation reduce therapy without compromising outcome Individualized patient management - risk adapted - response adapted

  27. 4x CHOP-R Early Response Assessment prior 1x CHOP-R 8 x CHOP-R

  28. Early PET in HL Hutchings et al, Blood 2005 Prospective study, 77 pts, 48 stage I/II PET after 2 cycles

  29. Early Response Assessment by PET Optimal timing? Definition of PET response (quantification)?

  30. Timing of early PET?? Need for quantification Baseline PET-CT PET-CT after 1 cycle CHOP-R The patient with DLBCL obtained a complete remission on PET after 3 cycles of CHOP and is still progression free after 16 months follow-up  very early after initiation of therapy: need for quantification???

  31. Timing of early PET?? Need for quantification PET-CT after 1 week CHOP-R Baseline PET-CT The patient became clinical progressive during treatment and died of lymphoma only 3 months after initial diagnosis.  very early after initiation of therapy: need for quantification???

  32. Time of diagnosis Start chemotherapy Death Symptoms Number of malignant cells PET-detection Cycles of chemo Time Chemosensitivity Chemoresistance

  33. Quantification of early PET? • Hutchings, Blood 2005 • SUVmax = 4 is optimal? HD after 2-3 cycles • Kostakoglu, Cancer 2006 • SUVmax = 1.75 (sens 92%, spec 84%) HD/DLBCL after 1 cycle • Torizuka, EJNM 2004 • Decrease SUV of -60% HD/NHL after 1-2 cycles

  34. Figure V.1. Complete remission on early FDG-PET. • (A)Pretreatment PET/CT shows an intense FDG-avide lesion left hilair. • (B) Early PET/CT shows a slighly increased FDG-uptake but not exceeding • mediastinal blood pool uptake. Also an important response is seen on CT. • (C) Interim and • (D) end-of-treatment PET/CT show persistent complete remission. • This patient is in sustained complete remission after 30 months follow-up PET after 1 week CHOP-R in DLBCL (29 patients) • Prospective study • Newly diagnosed DLBCL • PET after 7 days CHOP-R • 12 patients negative on early PET • 12/12 disease free after a median follow-up of 19 months

  35. PET after 1 week CHOP-R in DLBCL (29 patients) • 17 patients positive on early PET • 2/17 refractory disease • 2/17 relapsed (12, 23 mts) Residual FDG-uptake on early PET Patient A never obtained a complete remission and refractory disease was histologically proven based on end-of-treatment PET/CT

  36. PET after 1 week CHOP-R in DLBCL (29 patients) • 17 patients positive on early PET • 13/17 disease free after a median follow-up of 20 months • Quantification???? • No significant difference in absolute uptake values • High variability in percentage decrease (B) Despite a significant residual uptake on early PET, this patient obtained a complete remission at interim PET, and is still disease free after a follow-up of 29 months

  37. PET after 1 week of therapy • early PET: • sensitivity 100%, specificity 48%, NPV 100%, PPV 24%  Negative on early PET: excellent prognosis, reduction of therapy?  Positive on early PET: low specificity, quantification not better than visual interpretation

  38. PET for Early Therapy response: Conclusion • Persistent FDG uptake after 2-3 cycles of chemo is associated with a high probability of relapse at the end of treatment Early PET response is a stronger predictor of PFS than IPI or IPS • Optimal timing? Definition of PET response (quantification)?

  39. Chemo A Chemo A Baseline PET Early PET PFS & OS Chemo B Conclusions • PET for RESIDUAL DISEASE in aggressive NHL and HL • IWC+PET for end-of-treatment evaluation • Persistent FDG uptake after a 2-3 cycles of chemo is associated with a high probability of relapse • PET for measuring CHEMOSENSITIVITY in the other histological subtypes: IWC+PET criteria not recommended in MCL • Early PET at more early time points and Optimal timing? Definition of PET response (quantification)? • Will PET-adapted treatment improve overall survival? (Dann, Blood 2007, PET after 2 cycles in HL, reduction of cumulative dose of chemotherapy without impairment of outcome.) !!!! Need for prospective trials

More Related